Japan is considering increasing the stockpile of Fujifilm Holding Corp’s Avigan anti-flu drug during this fiscal year so that it can be used to treat 2 million people, according to a planning document seen by Reuters.
Local media yesterday reported that Japan was hoping to triple the production of the drug from current levels, which is enough to treat 700,000 people if used by COVID-19 patients.
Avigan, also known as favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014. Avigan is being tested in China as a treatment for COVID-19.
In the emergency stimulus package expected to be rolled out tomorrow, the government also plans to prioritize the clinical trial process of the drug so that it can be formally approved to be used in treating coronavirus patients.
According to the document, Japan also plans to boost subsidies to domestic companies that supply masks and disinfectants, and would secure enough capacity to supply 700 million masks a month.
The Nikkei newspaper reported that in efforts to reduce its dependence on China as its manufacturing hub, it would subsidize companies that would move some of their production facilities back to Japan.
Japanese Prime Minister Shinzo Abe on Friday said that a stimulus package to combat the pandemic would target small firms and households hardest hit by social distancing policies that are affecting consumption.
The package would include cash payouts to small firms and households facing sharp falls in income, Abe said.
The government would also urge private financial institutions to join government-affiliated lenders in offering zero-interest rate loans to cash-strapped small and medium-sized firms, he said.
Separately, Gilead Sciences Inc said it is donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.
The drug would be offered for compassionate use, expanded access and clinical trials, and would treat patients with severe symptoms, chairman and chief executive officer Daniel O’Day said in an open letter.
The company is also boosting its supply of remdesivir to more than 500,000 treatment courses by October and to more than 1 million by the end of the year.
Production time has also been accelerated to six months from one year, he said.
“While we are working with the utmost sense of urgency on the immediate needs before us, we are also looking forward,” he said. “Over the next weeks and months, we will be able to further increase our supplies of remdesivir as raw materials with long lead times become available for manufacture.”
The drugmaker last week said that it was switching to “expanded access” from a “compassionate use” program under which remdesivir was given.
Additional reporting by Bloomberg
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the